Crystallization of Four Troglitazone Isomers: Selectivity and Structural Considerations
Source abstract
Abstract
The control of crystal form in chiral active pharmaceutical ingredients (APIs) is a critical challenge in pharmaceutical development, as differences in solid-state structure can significantly influence physical properties and manufacturing performance. Troglitazone, a molecule with two chiral centers, exists as four stereoisomers (RR, SS, RS, SR) that crystallize as two enantiomeric pairs: RR/SS and RS/SR. This study aims to elucidate the relationship between solution-state molecular interactions and crystallization behavior of these diastereomeric pairs. Antisolvent crystallization experiments were conducted for both mixed solutions containing all four isomers and solutions of individual pairs. Crystallization kinetics were monitored by HPLC, and the resulting solids were characterized by PXRD, DSC, TG, and microscopic observation. Nucleation induction times were determined over a range of supersaturation levels. To probe intermolecular interactions in solution, NOESY and targeted NOE NMR experiments were performed, and the results were compared with crystallographic data. The RS/SR crystals(H-form) consistently exhibited shorter induction times and faster crystallization rates than the RR/SS crystals (L-form), even under conditions where RR/SS solutions were more supersaturated. In mixed solutions, H-form crystallized preferentially, with L-form either remaining in solution or being incorporated into H-form crystals as a solid solution. NOESY and NOE analyses revealed intermolecular proximities between protons that are distant in the molecular structure, indicating the presence of ordered aggregates in solution. These aggregates were more structurally compatible with the H-form than with the L-form crystal lattice, as supported by crystallographic distance analysis. The results demonstrate that differences in nucleation kinetics between troglitazone diastereomers are closely linked to solution-state molecular arrangements. Understanding these relationships provides a molecular-level basis for the rational design of selective crystallization processes for chiral APIs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystallization and Solubility Studies · Chemistry and Stereochemistry Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Daiichi Sankyo Co., Ltd., Hiratsuka 254-0014, Japan
Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, Osaka 558-8585, Japan
Kansai Chemical Engineering Co., Ltd., Amagasaki 661-0024, Japan
References (22)
Show source-provided references
1. Bernstein, J. (2002). Polymorphism in Molecular Crystals, Oxford University Press.
2. Hilfiker, R. (2006). Polymorphism in the Pharmaceutical Industry, Wiley-VCH.10.1002/3527607889 ↗
3. Amorphous pharmaceutical solids: Characterization, stabilization, and development of marketable formulations of poorly soluble drugs with improved oral absorption10.1021/mp800203k ↗
4. International Council for Harmonisation (ICH) (1999). Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, ICH.
5. U.S. Food and Drug Administration (FDA) (2007). Guidance for Industry: ANDAs—Pharmaceutical Solid Polymorphism, Chemistry, Manufacturing, and Controls Information, FDA.
6. Pharmaceutical digital design: From chemical structure through crystal polymorph to conceptual crystallization process10.1021/acs.cgd.3c01390 ↗
7. Chiral drugs: An overview10.59566/IJBS.2006.2085 ↗
8. Semi-continuous and continuous processes for enantiomeric separation10.1039/D1GC03668H ↗
9. Strategies for chiral separation: From racemate to enantiomer10.1039/D3SC01630G ↗
10. Design of diastereomeric salt resolution via multicomponent system characterization: A case study with hydrate formation10.1039/D2CE01490D ↗
11. Recent advances in the field of chiral crystallization10.1002/chir.23492 ↗
12. Advances and applications of chiral resolution in pharmaceutical field10.1002/chir.23453 ↗
13. Continuous crystallization processes in pharmaceutical manufacturing: A review10.1021/acs.oprd.0c00398 ↗
14. Al-Sulaimi, S., Kushwah, R., Abdullah Alsibani, M., El Jery, A., Aldrdery, M., and Ashraf, G.A. (2023). Emerging developments in separation techniques and analysis of chiral pharmaceuticals. Molecules, 28.10.3390/molecules28176175 ↗
15. The driving mechanism behind attrition-enhanced deracemization. Angew10.1002/anie.201002036 ↗
16. Temperature cycle induced deracemization10.1016/j.mencom.2020.07.002 ↗
17. Innovative chiral resolution using enantiospecific co-crystallization in solution10.1021/cg300307z ↗
18. Physicochemical properties and crystal structure of troglitazone polymorphs10.1248/cpb.51.807 ↗
19. Physical property of troglitazone, an equal mixture of four stereoisomers10.1016/S0378-5173(02)00430-1 ↗
20. Separation of non-racemic mixtures of enantiomers: An essential part of optical resolution10.1039/b917564d ↗
21. Do amorphous troglitazones prepared from two diastereomer-pairs have the same molecular mobility and crystallization rate at the surface?10.1248/cpb.59.1452 ↗
22. Crystallization behavior of taltirelin polymorphs in a mixture of water and methanol10.1016/S0022-0248(99)00903-3 ↗